Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WOLF TICKETS 2022
InMed Pharmaceuticals is a global leader in the manufacturing and development of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness.Oct 15, 2021
InMed Pharmaceutical (INM)
1.44 ? -0.07 (-4.64%)
Volume: 305,289 @11/05/21 7:37:12 PM EDT
Bid Ask Day's Range
1.4 1.48 1.43 - 1.52
INM Detailed Quote
Financial bukkake ! BAAHHAHAHAHHAHAHAAA
I always love to see & feel the pure raw emotion that comes after people have lost all of their $$$$.
Even as they still cling to the hope that Eric Ashley Adams will one day ride in on a white horse and return their money.
Whether it be Mr Wolf Tickets, who was savaged into surrender not only in the octagon, but also knelt helpless on the dirt floor of his Stockton garage as he watched his portfolio implode all over him. A financial bukkake. & not the kind that he usually receives o no.
Then there is the consummate bagholder greendragoon000. Watched helplessly for years as Adams picked him clean & now only able to squeak out profanities as he literally is clueless as fcuk still.
I toast both of you from afar. One went down swinging, the other just went down on.........
Adios MF's adios
Wolf Tickets 2022 as Dr. Bill Garner pulls his wire & thinks about all of the suckers who financed his Puerto Rican estate.
I agree with Diaz
Fuck fair weather BOBIN
Only thing it is good at is giving head and I’m not talking advice
All those who tapped out, leave your comments to yourself
All those who were accumulating on the way down, blessed
WOLF TICKETS 2021
TODAYS CLOSE
209
BOBIN CAN FUCK OFF
DIAZ BLESS
WOLF TICKETS 2021
https://m.canadianinsider.com/node/7?ticker=INM*US
WHERE U AT ASHLEY, WHERE U AT MOTHEFUCKER
BOBIN IM NOT SURE WHAT TO MAKE OF UR OPINION..MAYBE DONT WATCH NEXT TIME?? STAY IN UR LANE HOMIE
DIAZ BLESS
Nick my man, your performance last night reminded me of Inmed stock. Disgraceful.
InMed Pharmaceutical (INM)
1.89 ? -0.03 (-1.56%)
Volume: 237,288 @09/22/21 7:47:23 PM EDT
Bid Ask Day's Range
1.86 1.88 1.8 - 1.92
INM Detailed Quote
WOLF TICKETS 2021
Share price will likely hang out at 209 or so until September 25th. Don't get me wrong I have been right before.
After hours was poppin last week
Wait til the countdown or embedded gets released
Diaz bless
WOLF TICKETS 2021
InMed Pharmaceutical (INM)
2.45 ? -0.02 (-0.81%)
Volume: 37,191 @08/13/21 6:56:47 PM EDT
Bid Ask Day's Range
2.45 2.85 2.4 - 2.5
INM Detailed Quote
WOLF TICKETS 2021
Was fuckin around the other day doin my finances and took $2.50 and divided it by 33. Looked around at my surroundings after figuring it out. All I can say is A GENTLEMAN NEVER TELLS, A GENTLEMAN NEVER TELLS
DIAZ BLESS
wolf tickets here. will short to 2.09 and get back in, Ashley or Madcini will want to dump shares so pump will be arranged. Rinse and repeat. Wolf tickets
InMed Pharmaceutical (INM)
2.93 ? 0.06 (2.09%)
Volume: 61,458 @07/09/21 7:03:45 PM EDT
Bid Ask Day's Range
2.78 3.0 2.7642 - 2.93
INM Detailed Quote
Ashley Adams is a pos
Lawsuits? Please give more details. Thank-you>
If and when the lawsuit(s) are filed, I'm def in.
Take notes of how it's done by companies that execute on schedule.
https://www.prnewswire.com/news-releases/willow-biosciences-and-cellular-goods-announce-multiyear-supply-agreement-for-cannabigerol-cbg-301309618.html
InMed Pharmaceutical (INM)
2.895 ? 0.025 (0.87%)
Volume: 97,033 @05/26/21 1:47:27 PM EDT
Bid Ask Day's Range
2.87 2.91 2.8 - 3.0
INM Detailed Quote
This forum gets about as much action as InMed's execution plans
Never sold a share.
Dickie Diamond Hands
I also have been critical of EA over these recent years and there may be truth as some have stated on many occasions that he's little more than Schneider's puppet. The broader market has shown to also have little confidence in their execution as the news released today, in other times or places would have been significant, barely moved the needle of this perennial dumpster fire.
Yes, the defensive clowns have all but mostly disappeared along with their investments. They are the only ones that have to live with their own stain of credibility, recorded forever in the archives of the forum.
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™
This yield level demonstrates commercial viability; supports advancing to large-scale production
April 26, 2021
https://www.globenewswire.com/news-release/2021/04/26/2216720/36215/en/InMed-Pharmaceuticals-Achieves-2g-L-Cannabinoid-Yield-with-IntegraSyn.html
VANCOUVER, British Columbia, April 26, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that its IntegraSyn™ cannabinoid manufacturing approach has achieved a level of 2g/L cannabinoid yield, a milestone that signals commercial viability and supports advancement to large-scale production in the coming months.
For its first application using the IntegraSyn™ approach, InMed set two main objectives to enable a cost-effective solution to cannabinoid production: to achieve a commercially viable yield higher than current industry standards and to lower overall manufacturing costs through process optimization. InMed’s IntegraSyn™ manufacturing approach was able to achieve both objectives. IntegraSyn™ utilizes an enzymatic biotransformation process as a part of an overall integrated cannabinoid manufacturing approach to overcome certain natural yield limitations of traditional biosynthesis for full cannabinoid assembly. Having achieved a 2g/L yield level, InMed will now focus on manufacturing scale-up to larger batch sizes while continuing process and enzyme optimization, targeting increased cannabinoid yield and further reducing the overall cost of goods. In parallel, the Company continues to prepare the manufacturing process to be Good Manufacturing Practice (GMP)-ready for pharmaceutical quality production. The next stage of large-scale production is to produce a batch with a target output of one kilogram of the selected cannabinoid in 2H2021 via a GMP-ready process.
“We are very pleased to have achieved this high yield at this stage and are looking forward to applying the IntegraSyn™ approach to large-scale production. As this scale-up progresses, we will also seek to further optimize our manufacturing and purification processes and further enhance the enzyme design. These ongoing improvements will focus on achieving even higher yields, beyond the already impressive 2g/L,” commented Eric Hsu, Senior Vice President, Preclinical R&D. “I would also like to acknowledge the Almac Group, our collaborator and contract manufacturing partner, for bringing their extensive knowledge and expertise to the program as we reached this important milestone.”
Michael Woudenberg, Vice President of Chemistry, Manufacturing and Controls, added, “In addition to achieving a commercially viable cannabinoid yield level, we have focused on utilizing cost-competitive starting materials to enable a cost-effective solution to pharmaceutical-grade cannabinoid production with IntegraSyn™. We believe this is especially important in accessing rare cannabinoids.”
About InMed: InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.
About IntegraSyn™: IntegraSyn™ is InMed's integrated cannabinoid manufacturing system designed to efficiently and economically produce pharmaceutical-grade, bio-identical cannabinoids. The scalable and flexible IntegraSyn™ manufacturing system integrates multiple commercially proven methods to efficiently produce cannabinoids utilizing cost-effective processes.
About Almac Group: The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, Interactive Response Technology through to commercial-scale manufacture. Almac is an international, privately-owned organization which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia. For more information please visit almacgroup.com.
Investor Contact:
Edison Group
Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
E: jgreen@edisongroup.com
lyonker@edisongroup.com
Cautionary Note Regarding Forward-Looking Information:
Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: commercial viability and advancement to large-scale production and the timing thereof; the focus of the Company on manufacturing scale-up to larger batch sizes while continuing process and enzyme optimization, targeting increased cannabinoid yield and reducing overall costs; the preparation to be GMP-ready; IntegraSyn™ being able to efficiently and economically produce pharmaceutical-grade, bio-identical cannabinoids; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs; and the next stage being a target output of one kilogram of the selected cannabinoid in 2H2021 via a GMP-ready process. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: that the manufacturing approach means commercial viability and possible large-scale production; cannabinoid yield can be increased; overall costs can be reduced; the manufacturing process is possible to be GMP-ready for pharmaceutical quality production; and optimization of the manufacturing and purification processes and further enhancement of enzyme design is possible. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: the outbreak and impact of COVID-19 may worsen; commercial viability and large-scale production may not be possible within anticipated timelines or at all; the manufacturing process may not be GMP-ready for pharmaceutical quality production; demand or interest for InMed's products may decrease or cease; and economic and market conditions may become unstable or unfavorable. A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s filings with the Securities and Exchange Commission and the most recent Annual Information Form filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Dont forget that it's Schneider pulling Adams strings. They will just replace him with another corrupt yes man.
Oust that useless pos indeed. I wonder how the f he was even employed at powerhouse Abbott labs
Yep you can't argue with facts.
Everything you stated is factual and it goes to show the difference between good leadership and poor leadership. Adams has shown through his 5 year reign that he is a very poor CEO. I know it sounds like a broken record to say but he has embarrassingly bungled just about every aspect of this company and rendered them a non factor in what is probably the most exciting field of medicine in a decade.
It is a shame to see what Inmed has become. Adams is only interested in enriching himself (and his cronies) while he laughs at (and ignores) the shareholders.
It's funny to see that most of the long time "pumpers" have sold and moved on. They had mocked, berated and bullied anyone who dared bring up a questionable issue about Inmed.
The only viable path for Inmed to salvage any respectability and growth is to REMOVE ADAMS IMMEDIATELY!
Been so long I almost couldn't find my way back here. How's for a little recap since I've been on hiatus? InMed competitor in cannabinoid manufacturing Amyris has gone from low single digits to a high over $20 in less than a quarter. After completing batch runs Willow has been sending CBG samples all over the world and they're stock has about tripled in the same time period. They've stated to be producing CBG commercially in the next quarter.
InMed, our little thorn, with their flowery power points that go no where is currently trading at close to .08 pre-split levels. Incredible to see a company with an outstanding share count so low still manage to only keep going backwards on zero material news to release.
Maybe I'll stop back in a quarter when Willow is trading around $5.
Stay parched.
You all got sold Wolf Tickets.. now watch a real homey make bank riding this run up to the 5 dollar range....
DIAZ bless
Yes I admit, I was definitely a big believer in Inmed at one time. But years of the same old run around and absolutely no progress what so ever, nothing but presentations on our dime. Eating at the nicest restaurants and drinking the finest Champagne, staying at the most luxurious Hotels! Complete silence for months! Why does it take half a year or longer to file an application for ph 2 since ph 1 ended? Ridicules. There isn't any interest in Biosynthesis, at least not theirs! I think you're right, the executives are all lining their own pockets and not giving a care in the world about the retail investors! It's too bad!
Exactly! Remember how he used to argue with anyone who stated facts that weren't in line with his opinion?
He used to spew the same garbage that the "see you at 50" guy did as well as the "napkin math" guru on another site.
Remember folks, the only reason I started posting on here is to call out the pumpers (they are super dangerous) and speak the truth so we can all strive for honesty and transparency with the companies we invest in.
I've been cheated and lied to by the best of 'em and I'm not gonna let new investors fall for the same crap that I did decades ago.
Time to pull the curtain back on Adams and his foolishness. The time is coming real soon.......
Flair 09 out of the ashes re emerges, one of the biggest Inmed pumpers in history. Even he's out so the situation must be grave
This company is disgusting, I'm so glad I got out a few months back and made up my Inmed losses elsewhere. Good riddance!
Adams and crew scum of the earth
Anyone else catch this sneaky move by Adams and company?
I was looking over section 5.02 (compensatory arrangements of certain officers) and look what I found. The last pp in Feb. was done so that Adams, Colwill and Mancini could get a bonus! Well, well, well. How shocking.....
(f) Disclosure of Bonus Omitted From Summary Compensation Table of Registration Statement
As disclosed under the Summary Compensation Table in InMed Pharmaceuticals Inc.’s (the “Company’s”) registration statement on Form S-1, as amended, filed on October 8, 2020 and effective with the Securities Exchange Commission on November 12, 2020 (the “Registration Statement”), certain compensation of Eric A. Adams, the Company’s Chief Executive Officer and President, Bruce Colwill, the Company’s Chief Financial Officer and Secretary, and Alexandra Mancini, our Senior Vice President, Clinical and Regulatory Affairs (together, the Company’s “NEOs”) for the fiscal year ended June 30, 2020 could not be calculated as of the date of the filing of the Registration Statement, as such compensation had not yet been determined by the Company’s Compensation Committee. The Registration Statement mistakenly stated that the amounts unable to be determined at the time of filing were non-equity incentive plan compensation, but should have indicated that such undetermined amounts were bonus awards.
Subsequently, on November 30, 2020, the NEOs were awarded bonuses as follows: Mr. Adams received $67,505, Mr. Colwill received $42,580 and Ms. Mancini received $38,284. This award reflected 50% of the NEOs potential bonus.
In addition, on February 26, 2021, following the completion of the Company’s private placement on February 12, 2021, the NEOs received additional bonus amounts, equal to the November 30, 2020 awards, as follows: Mr. Adams received $67,505, Mr. Colwill received $42,580 and Ms. Mancini received $38,284.
Adams and his crew are literally giving themselves bonuses to dilute the company into oblivion!
InMed Pharmaceutical (INM)
3.05 ? 0.02 (0.66%)
Volume: 62,065 @04/16/21 7:08:07 PM EDT
Bid Ask Day's Range
2.93 4.02 2.92 - 3.01
INM Detailed Quote
Adams has been well compensated as he plunders this company. But dont lose sight of the fact that he has little or no say in decision making. Schneider & to a lesser degree Bogie are pulling his strings like a dancing puppet.The two of them before the consolidation owned north of 25mil shares.
They’ve scaled up and have buying customers bud. Sounds like they’re way out ahead of inmed on the biosynthesis front
In Eric Adams own words:
"Integrasyn which we think is a way to optimally manufacture cannabinoids at a very low cost. Integrasyn is flexible and able to produce A WIDE RANGE OF CANNABINOIDS. Integrasyn is designed to be an efficient, scalable, flexible and economical solution to produce cannabinoids with bio identical structures to those found in nature. While traditional biosynthesis and chemical synthesis focus on production of one cannabinoid from start to finish, the modular IntegraSynTM processes provide flexibility to shift production of one cannabinoid to a range of cannabinoids. This modular approach places less burden on the fermentation microbe and allows for the use of different enzymes and starting materials, leading to optimized yield, time and cost."
Sounds like they've found the cannabinoid holy grail.
He makes it sound like they can produce just about any cannabinoid they want cheaply, purely and quickly.
They should be screaming this from the mountain tops. Wonder why they aren't? Come on, we all know why...
There's nothing in that link that indicates that Willow is way ahead of InMed. They claim they can produce CBG on a commercial scale using yeast fermentation. Inmed claims that using E-coli makes the process more efficient and faster. To my knowledge, there isn't much of a market for CBG at this time yet their only unique claim is that they can produce it on a commercial scale. At this point, we don't really know that InMed can't do the same. The question is, could they sell it on a commercial scale.
Willow way ahead of Inmed :
https://thedeepdive.ca/willow-biosciences-first-commercial-fermentation-of-cbg-completed-the-daily-dive/
Eric Adams pos scammer
Followers
|
227
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
9998
|
Created
|
05/21/14
|
Type
|
Free
|
Moderators |
A drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids
InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
InMed is utilizing its proprietary bioinformatics assessment tool to identify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases. The goal is to identify new drug candidates that optimize therapeutic benefit while limiting adverse effects.
InMed’s proprietary in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.
Investment Highlights
Bioinformatics: Proprietary Drug / Disease Targeting Tool
InMed’s has developed a computer-based program to assist in the identification of novel cannabinoids using: (i) comprehensive algorithms to integrate data from numerous bioinformatics databases, (ii) a database on the structure of currently approved pharmaceutical products, and (iii) an extensive database on over 90 individual cannabinoid drugs found in cannabis.
Biosynthesis
Most of us are familiar with the two main bio-active ingredients produced by the cannabis (marijuana) plant, namely THC and CBD. In reality, however, there are 90+ cannabinoids in the plant that could have medical value but are too hard to research due to the fact that they only appear in trace amounts in each plant. InMed has developed, patented and intends to commercialize a process for producing all 90+ cannibinoids using genetically engineered bacteria to create bioidentical copies of these substances. Not only is their process less costly but it also produces these cannabinoids in large quantities at pharmaceutical grade purity. The following link provides a clear explanation of the process in laymen's terms.
Biosynthesis: The Science That May Unlock the Medical Potential of Cannabis
_________________________________________________________________________________________________________________________________________________________________________________
Pipeline
InMed is building a robust product pipeline through its proprietary discovery platform and research & product development programs. The company continues to seek innovative product candidates for the treatment in following therapeutic areas:
|
|
InMed's pipeline currently includes two drug candidates in preclinical development: INM-750 for the treatment of epidermolysis bullosa (EB); and INM-085 for the treatment of glaucoma.
INM-750
Referred to as "The Worst Disease You've Never Heard Of," EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. Through the development of INM-750, InMed is attempting to address this significant unmet medical need, for which there is no approved treatment or cure. INM-750 replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
Market Potential - Amicus Therapeutics recently acquired Scioderm, Inc. and its lead EB drug candidate, Zorblisa™, for $847 million. Notably, Scioderm's sole clinical asset was Zorblisa.
JP Morgan and Cowen Research Reports estimate that peak sales for Zorblisa could reach $900 million to $1.2 billion.
INM-085
INM-085 is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure.
Market Potential - The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease. Worldwide, glaucoma represents a market of $5.6 billion.
Leadership
InMed's management team has well over a century of combined experience in the biopharmaceutical space. Together, the professionals comprising this team are guiding InMed into exciting opportunities in the cannabis-pharma sector.
Eric A. Adams, President & CEO
Eric Adams is a seasoned biopharmaceutical executive with over 25 years of experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.
He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana aerospace industry, most recently with Metal Form, Inc., a privately held aerospace manufacturing company, where he served as president and CEO from 1987 to September of 1999.
Dr. Sazzad Hossain, Ph.D., M.Sc., Chief Scientific Officer
Dr. Sazzad Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.
Dr. Ado Muhammed, MD, DPM, MFPM, Chief Medical Officer
Dr. Ado Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs. His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role and others at GW Pharmaceuticals, Dr. Muhammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. Dr. Muhammed's received his MD at Ahmadu Bello University followed by an MSc in Orthopaedics at University College London. Dr. Muhammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff followed by an MBA in Business Administration at the University of Leicester. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.
Alexandra D.J. Mancini, M.Sc., Senior Vice President, Clinical and Regulatory Affairs
Alexandra Mancini has over 30 years' of global biopharmaceutical R&D experience with a particular emphasis on clinical development and regulatory affairs. Ms. Mancini has been an executive with several biotech companies, overseeing a wide range of drug development activities. As Sr. VP of Clinical & Regulatory Affairs at Sirius Genomics, her role included identifying and managing external resources for medical expertise in sepsis; clinical data management; and statistical theory, programming and analyses. While at INEX Pharmaceuticals as Sr. VP of Clinical & Regulatory Affairs, Ms. Mancini oversaw Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance for oncology. She served as VP of Regulatory Affairs at QLT Inc. for oncology and ocular diseases, playing a significant role in the development of VISUDYNER from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Ms. Mancini also led the regulatory approval process for the anticancer drug PHOTOFRINR and its associated medical devices, the first drug-device combination product approved by the US Food and Drug Administration. Ms. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions. Ms. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.
Jeff Charpentier, CFO, Chief Financial Officer
Jeff Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.
InMed Pharmaceuticals, Inc. | NetworkNewsWire |
NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer/
InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
Corporate Presentation
https://www.inmedpharma.com/site/assets/files/1343/jan-cp-2017-2.pdf
InMed Pharmaceuticals is currently developing two products in its drug pipeline: INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma.
Epidermolysis Bullosa (EB) is group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily from friction or trauma. Internal organs and bodily systems can also be affected by EB. It is a result in a defect of anchoring between the dermis and epidermis cause most frequently by the absence of certain keratins (or, proteins) in the skin. EB is an orphan disease with no currently approved treatments and has a significant unmet medical need. INM-750 will potentially be the first therapy designed and developed specifically to modulate disease activity and to alleviate symptoms in EB.
INM-750 includes multiple cannabinoids as the active ingredients:
INM-085
Glaucoma is a group of eye disorders which result in damage of the optic nerve. The damage is most often caused by an abnormally high pressure in the eye and is one of the leading causes of blindness in the developed world.
INM-085 will be the first ever glaucoma treatment developed that is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. The cannabinoids in INM-085 have been selected to reduce the elevated intra-ocular pressure (IOP) in the affected eyes and provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues.
INM-085 is designed as a topical formulation to be administered directly to the eye. The formulation that has been designed by InMed is a proprietary polymer-based formulation to facilitate absorption of the cannabinoids into the eye while also being well tolerated by the patients. We envision a once-a-day application, at bedtime, to deliver effective dose levels of INM-085.
Proposed Targets to Develop Drugs From Cannabis and Other Botanical Sources
Dermatology
Ocular
Pain and Inflammation
CNS
Respiratory
Metabolic Disease
The majority of pharmaceutical and academic research & development activities being performed with cannabis revolves around the understanding of its biologically active ingredients, the Cannabinoids
Currently there are 90+ cannabinoids that have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for unique pharmacological effects.
There are three general types of cannabinoids: herbal cannabinoids which occur uniquely in the cannabis, endogenous cannabinoids produced in the bodies of humans and animals and synthetic cannabinoids produced in the laboratory.
Cannabinoid Receptors
Before the 1980s, it was often speculated that cannabinoids produced their effects through nonspecific interaction with cell membranes, instead of interacting with specific receptors. The discovery of the first cannabinoid receptors in the 1980s helped to clarify their role. These receptors are common in animals, and have been found in mammals, birds, fish and reptiles. There are currently two known types of cannabinoid receptors, called CB1 and CB2.
CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems. CB1 receptors are essentially absent in the medulla oblongata, the part of the brain that is responsible for respiratory and cardiovascular functions. Thus, there is not a risk of respiratory or cardiovascular failure as there is with many other drugs. CB1 receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis.
CB2 receptors are almost exclusively found in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis.
The protein sequences of these two receptors are about 45% similar. In addition, minor variations in each receptor have been identified. There is some indication that other receptors exist, but none have been confirmed. Cannabinoids bind reversibly and stereo-selectively to the cannabinoid receptors. The affinity of an individual cannabinoid to each receptor determines the effect of that cannabinoid. Cannabinoids that bind more selectively to certain receptors are more desirable for medical usage.
Herbal Cannabinoids
Herbal cannabinoids are nearly insoluble in water but soluble in lipids, alcohols and other non-polar organic solvents. All herbal cannabinoids are derived from their respective 2-carboxylic acids (2-COOH) by decarboxylation that is, catalyzed by heat, light, or alkaline conditions. Herbal cannabinoids occur naturally only in the cannabis plant, and are concentrated in a viscous resin that is produced in glandular structures known as trichomes. In addition to cannabinoids, the resin is rich in terpenes, which are largely responsible for the odor of the cannabis plant.
There are over ninety known herbal cannabinoids. Of these, tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent and have received the most attemtion. Other common cannabinoids include:
CBG | Cannabigerol |
CBC | Cannabichromene |
CBL | Cannabicyclol |
CBN | Cannabidiol |
CBV | Cannabivarol |
THCV | Tetrahydrocannabivarin |
CBDV | Cannabidivarin |
CBCV | Cannabichromevarin |
CBGV | Cannabigerovarin |
CBGM | Cannabigerol Monoethyl Ether |
THC is the primary psychoactive component of the plant. Medically, it appears to mediate pain and to be neuroprotective. THC has a greater affinity for the CB1 receptor than for the CB2 receptors. Its effects are perceived to be more cerebral.
CBD is not psychoactive, and appears to mediate the euphoric effect of THC. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver. Medically, it appears to relieve convulsion, inflammation, anxiety, and nausea. CBD has a greater affinity for the CB2 receptor than for the CB1 receptor. It is perceived to have more effect on the torso than on the brain or CNS.
Cannabinoids were first discovered in the 1940s. The structure of THC was first determined in 1964. Due to molecular similarity and ease of synthetic conversion, it was originally believed that CBD was a natural precursor to THC. However, it is now known that CBD and THC are produced independently in the cannabis plant.
Cannabis plants can exhibit wide variation in the quantity and type of cannabinoids they produce. The mixture of cannabinoids produced by a plant is known as the plant’s cannabinoid profile. Selective breeding has been used to control the genetics of plants and modify the cannabinoid profile. For example, strains of hemp, which are used as fiber, are bred such that they are low in psychoactive chemicals like THC. Strains used in medicine are often bred for high CBD content, and strains used for recreational purposes are usually bred for high THC content, or for a specific chemical balance. Some strains of more than 20% THC have been created.
Cannabinoids can be administered by: smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Once in the body, most cannabinoids are metabolized in the liver, although some is stored in fat.
Cannabinoids can be separated from the plant by extraction with organic solvents. However, to produce high purity, cannabinoid chemical synthesis or semisynthesis is generally required.
University of British Columbia
Department of Chemical & Biological Engineering
Vancouver Campus
2360 East Mall
Vancouver, BC Canada V6T 1Z3
Department of Pharmaceutical Sciences
Vancouver Campus
2405 Westbrook Mall
Vancouver, BC, Canada V6T 1Z3
University of Debrecen
Research Center for Molecular Medicine, Department of Physiology
1H-4032 Debrecen, Nagyerdei krt. 98
Hungary
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |